The unsolved issue with limited evidence: antiplatelet therapy during the chronic maintenance period after percutaneous coronary intervention

EuroIntervention 2022;18:e355-e356. DOI: 10.4244/EIJ-E-22-00019

Hyo-Soo Kim
Hyo-Soo Kim1, MD, PhD; Jeehoon Kang1, MD
1. Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea
Over the past 20 years, interventional cardiologists have tried to give an answer to a very simple question, “What is the optimal antiplatelet regimen after percutaneous coronary intervention (PCI)?” More than 40 randomised clinical trials have been performed, but we still do not have a concrete conclusion. Currently, an individualised risk stratification and personalised medicine seem to be the answer. There has been a paradigm shift (or expansion) in the way that antiplatelet agents are prescribed in clinical practice. In the past, the targets of antiplatelet agents were local factors (stent-related), therefore finding a strategy that reduced PCI-related ischaemic events ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
New paradigms for the sequential treatment of severe aortic stenosis: imaging-guided selection of the first intervention paves the way for lifetime management

Latest news